Skip to main content

RA Capital Healthcare Fund LP's Form 4 filing

Vor Biopharma Inc.VOR · filed Oct 22, 2025

Accession no.
0001231919-25-000342
Filed
Oct 22, 2025, 7:48 PM ET
Trade date
Oct 20-21, 2025
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 5 non-derivative transactions. Open-market sales total $3.43M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
RA Capital Healthcare Fund LPCIK 0001315082Director, 10% Owner
Ra Capital Management, L.P.CIK 0001346824Director, 10% Owner
Kolchinsky PeterCIK 0001384859Director, 10% Owner
Shah Rajeev M.CIK 0001619841Director, 10% Owner
RA Capital Nexus Fund, L.P.CIK 0001780117Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 20, 2025Common StockSSaleDisposed−70,366$29.63F1−$2,084,944.581,432,806Indirect
Oct 20, 2025Common StockSSaleDisposed−13,817$29.63F1−$409,397.711,287Indirect
Oct 20, 2025Common StockSSaleDisposed−6,553$30.12F5−$197,376.361,426,253Indirect
Oct 20, 2025Common StockSSaleDisposed−1,287$30.12F5−$38,764.440Indirect
Oct 21, 2025Common StockSSaleDisposed−25,027$28.11F6−$703,508.971,401,226Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.045 to $30.025 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 2 transactions in Table I.

F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.05 to $30.26 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 2 transactions in Table I.

F6

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.475 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Remarks

Ms. Sarah Reed, General Counsel of the Adviser, serves on the Issuer's board of directors.

Read the full filing on SEC EDGAR (opens in a new tab)